studies

More documents

Recommendations

Info

1368A CATEGORY INDEX HEPATOLOGY, October, 2015 No Detectable Resistance to 1678 Novel robust in vitro hepati 1679 Possible involvement of hepa 1669 Serial Changes of Th1 and Th 1682 The Association of vitamin D 1662 The activating receptor NKP4 1657 The role of HBV quasispecies 1686 Unique Liver Transcriptomic 1637 EO2. Diagnostics, Epidemiology, Prevention, and Natural History Aldehyde dehydrogenases-2 rs 1580 Application of Highly Sensit 1573 Assessing the impact of hepa 1546 Baseline quantitative hepati 1604 Clinical Features of Chronic 1587 Clinical outcome of long-ter 1581 Clinical scoring system for 1616 Comparative Study for Anti-H 1599 Conconrdance between transie 1621 Different DNA methylation pa 1553 Evaluation of HBV infection 1622 Four years real-life experie 1544 Genotype-Specific Prevalence 1559 HBV-related cirrhosis in the 1578 Hepatitis B Core-Related Ant 1585 Hepatitis B Core-Related Ant 1586 Hepatitis B virus infection 1543 Hepcidin: A new clinical fac 1620 High Rates of Surface Antige 1549 Individualizing Hepatitis B 1560 Liver fibrosis progression, 1548 Long term clinical outcome i 1558 Lower Incidence of Hepatocel 1561 Mapping HBsAg epitope profil 1551 Nationwide Prospective Surve 1577 Objective Determination of H 121 PreS mutations analyzed by d 1565 Prevalence and Molecular Vir 1566 Prevalence and serological f 1555 Prevalence of Hepatitis B vi 1596 Relationship between hepatoc 126 Risk assessment of hepatocel 1605 Seroprevalence and Clinical 1598 Targetting HNF4α via Activa 1562 The Predictive Values of Hep 246 The Usefulness of CLIF-SOFA 1609 The role of hepatitis B core 1550 Utility of quantitative hepa 1576 Angiopoetin-like protein 2 i 1564 Anti-platelet therapy reduce 1610 Assessment Of Treatment Resp 1624 Assessment of liver steatosi 1582 Barriers to obtaining approp 1608 Baseline Hepatitis B core re 1572 Biomarkers of Fibrosis in Lo 1607 Changes in hepatitis B virus 1584 Changes of Hepatitis B surfa 1615 Characterization of Nucleic 1603 Clinical Outcomes of Patient 1556 Collaborative Public Health 1574 Comparing antiviral efficacy 1542 Comparison between spontaneo 1552 Detection of genetic and epi 1554 Does Cesarean section and fo 1619 Elevated serum levels of WFA 1600 End-of-therapy Serum Gradien 1547 Evaluation of Chronic Hepati 1606 Evaluation of Serum Cell Dea 1611 Factors Associated with the 1545 HBsAg transferring from moth 1579 Health care disparity in del 1569 Hepatic B flares in rheumato 1589 Hepatitis B viral load in dr 1575 Hepatocellular Carcinoma (HC 125 Hepatocellular Carcinoma Inc 1540 High-throughput and ultrasen 1614 Identification of a non-inva 1601 Inadequate Treatment of Chro 1625 Increased Viral Diversity is 1557 Influence of the ethnic stat 1613 Interleukin-2 Receptor and T 1602 Is booster beneficial after 1623 Is there any rule for antivi 1541 Kinetics of Serum Hepatitis 1567 Length of antiviral therapy 122 Longitudinal analysis of com 1595 Performance Assessment of Co 1618 Performance of the new cobas 1597 Postpartum hepatic flare aft 1617 Prediction of Clinical Outco 1591 Prevention of perinatal tran 1583 Quantitative Hepatitis B sur 1571 Redefining the Natural Histo 1563 Serum Alanine Aminotransfera 123 Serum HBV RNA is an early ma 1594 Serum Quantitative Levels of 1593 Statin and the risk of hepat 1612 The PAGE-B Score Accurately 1590 The PAGE-B Score Stratifies 1568 The Role of Surface Antibody 1592 Ultrasound predicts steatosi 1570 What is predicting post-preg 1588 EO3. Therapeutics: New and Approved “Real Life” outcomes for Ten 2047 A Multicenter, Prospective, 2048 A Randomized Prospective Ope 1995 A randomized study of standa 1997 A study to evaluate the dyna 2028 Association between Pre-S2 D 2040 Association between ALT flar 2059 Association of Interferon-ga 2036 Baseline HBsAg titer allows 2045 Biochemical, Virologic, and 243 Biologic Responses to GS-477 2052 Characterization of Hepatiti 2026 Comparative Effectiveness of 244 Comparison of the efficacy o 2055 Decreasing risk of hepatocel 2012 Discontinuation of Antiviral 2049 Discontinuation of Effective 2019 Dynamics of hepatitis b viru 2066 Early Decline in Serum HBsAg 2014 Early prediction of response 2001 Efficacy and Safety of Pegin 2023 Encapsidation and secretion 2064 Final Results of Peginterfer 2002 GalNAc-siRNA conjugate ALN-H 36 Inhibition of Hepatitis B Vi 33 Intrahepatic IP-10 expressio 2046 Liver Gene Expression Profil 2027 Long Term Efficacy and Safet 2004 Long term follow up of chron 2017 Longitudinal PAGE-B Scores P 2003 Monthly dosing of ARC-520 in 2022 Nucleos(t)ide Analogue Disco 1998 Nucleos(t)ide Analogues agai 242 Plasma MicroRNA Levels are A 2005 Prolongation of interferon t 2033 Reduction of HBsAg by peg-in 2029 Reductions in cccDNA under N 32 Safety and Efficacy of GS-47 2015 Serologic and Virologic Chan 2043 Serum HBV RNA is an Early Pr 245 Serum hepatitis B core-relat 2063 Tenofovir Disoproxil Fumarat 209 The New Cyclophilin Inhibito 2035 The baseline combination of 2044 The incidence and predictors 2010 The relationship between pat 2057 Treatment and HBeAg-status D 241 Urinary β2-microglobulin fo 1999 Week 24 HBsAg levels predict 2013 Whole-Genome Sequencing of P 2037 A randomized trial evaluatin 2038 Antiviral Activity of Tenofo 2021 Antiviral treatment for chro 2060 Bone toxicity during long-te 2053 Characterization of HBsAg lo 2032 Combined hepatitis B core-re 2020 Descriptive Comparison of Ef 2025 Development and Recurrence o 2065 Development of a Direct RNA 2062 Dual-gRNAs and gRNA-microRNA 34 Entecavir and Tenofovir More 2016 Excellent outcomes of hepati 2000 Functional Activation of NK 2009 HBV Does Not Modulate the Tr 35 Impact of pre-treatment plat 2031 Is efficacy of tenofovir in 2042 Long-Term Clinical And Serol 2008 Long-term Renal Safety of Ad 2056 NGAL can act as a renal safe 2054 Prediction of sustained off- 2050 Reduction of hepatocellular 1996 Safety, antiviral activity, 2058 Sequential therapy with Peg- 2030 Study on post-treatment rela 2061 TKM-HBV, a Novel RNA Interfe 2007 TKM-HBV, a Novel RNA Interfe 2034 Tenofovir-associated Fanconi 2006 The Efficacy And Safety Of T 2024 The Relationship Between Tel 2051 The combination of IFN-Lambd 2011 The impact of timely initial 2018 Update on the safety and eff 31 Hepatitis C FO1. Virology, Pathogenesis, and Immunology A methyl donor, S-adenosylme 1022 Alcohol increases the produc 30 Altered frequencies and func 1007 Analysis of genetic variatio 1028 Daclatasvir and Sofosbuvir i 217 Different HCV genotypes have 999 Elevation of Galectin-9 is a 26 Elucidating Mechanisms Under 1017 Evaluatiin of protective and 992 Evolution Of Resistance Asso 220 Expression of IFNλ4 in live 1018
HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) CATEGORY INDEX 1369A Fast and deep early HCV-RNA 222 HCV RNA and HCV core antigen 1002 HIV and HCV co-infection in 25 Individualized DAA treatment 982 Interferon lambda 3 (IL28B) 980 Iron chelation restores mito 995 Lipid-Free apolipoprotein E 1019 Liver pDCs from HCV-Infected 988 Long noncoding RNAs regulate 991 MicroRNA 17 Host Gene Protei 1011 Persistence of HCV-specific 1031 Polymorphisms in irisin-prod 221 Pre-treatment levels of miR- 1023 Rapid normalization of antiv 28 Role of very-low-density lip 997 Selenoprotein P regulates th 990 Serial change of resistant a 1027 The Antibody response to hep 1033 The Emergence of NS5B Resist 219 The impact of HLA-DQs and IF 986 The roles of unphosphorylate 1025 The tumor suppressor IQGAP2 1015 Transcriptomic analysis of C 1029 Type III interferon response 1006 Variability of the hepatitis 1021 Very low prevalence of Hepat 1032 De novo formation and matura 27 A miR-122/miR-224-based mode 998 Activation of Hepatic Stella 29 Analysis of AL-516, a Novel 993 Cell-specific peripheral inn 996 Differential microRNA expres 1014 Downregulation of let-7 fami 1005 Effects of Resistance Mutati 985 Essential Factors for Recons 1003 Establishment and Characteri 1000 Establishment of A Novel Hep 989 Hepatitis C Genotype 4r Resi 1009 Hepatitis C virus facilitate 984 Interferon-based treatment a 1008 Kidney involvement in HCV Ch 983 LECT2 specifically induced b 1010 MicroRNA-130a inhibit HCV pr 981 Novel effect of NS5A inhibit 1013 PD-1 blockade enhances cytop 1001 Rapid Decline In Interferon 218 Regulation of Hepatitis C Vi 994 Single-strand RNA-induced mo 1016 Substitution in amino acid 7 1020 The FGL2:FcγRIIB Immunosupp 1012 The Hepatitis C Virus modula 987 The effect of sofosbuvir-bas 1030 The expression of Immune-miR 1026 Tim-3 Inhibits Monocyte Func 1004 FO2. Diagnostics, Epidemiology, and Natural History MICA SNP, but not DEPDC5, PN 1824 Hepatitis E in haematologica 1803 A Highly Specific and Sensit 85 A New Simple Quantitative Li 1849 Acute HCV recurrence after l 1889 Acute hepatitis and reactiva 1882 Age and Risk Factor-based Se 1823 Application of a Novel Hepat 1785 Benefits of HCV eradication 1808 Can HCV Antigen Testing Repl 1826 Cannabinoid receptor 2 (CB2) 1837 Cascade of Care for Hepatiti 1786 Cascade of Care of HCV & HIV 1891 Comparison of performance ch 1817 Correlates of Successful HCV 1892 Differential Progression to 1848 Dynamic change of α-fetopro 1873 Effectiveness and cost-effec 1845 Evaluation of liver and sple 1862 Evaluation of liver and sple 1879 Evaluation of the role of he 1890 Expanded eligibility to HCV 1861 Fibrosis Regression After He 1876 Healthcare Utilization and C 1883 Hepatitis C Seropositivity i 1822 Hepatitis C Virus (HCV) Mort 86 Hepatitis C Virus (HCV) Prev 1859 Hepatitis C Virus (HCV) Prev 1818 Hepatitis C and Renal Diseas 1867 Hepatocellular carcinoma (HC 1847 Highly accurate HCV genotypi 1812 Illegal drug use disclosure 1857 Incidence and Predictors of 90 Increasing Prevalence of Cir 88 Investigation into the high 1865 Linkage to Care and Treatmen 1874 Low HCV Treatment for Chroni 1816 Male gender, genotype 3, pre 1844 Mathematical model for early 1821 Modeling the probability of 1854 Non-invasive assessment of l 1834 Performance of HCV Ag quanti 1833 Policy Implications of Dispr 1813 Pragmatic Non-invasive test 1856 Prevalence and Risk-Factors 1853 Prevalence of diabetes and a 1877 Prevalence of hepatitis B co 1850 Prevalence of viral hepatiti 1796 Progression to liver cirrhos 1806 Rate and Predictors of Serum 1881 Repeated biopsies within 23 1878 Risk of hepatitis C virus in 1793 Safety and Efficacy of Inter 1885 Screening Urban Baby Boomers 1835 Self-reported Alcohol Use at 1880 Stability and prevalence of 1832 The Utility and Limitations 1799 The hepatitis C epidemic amo 1830 The influence of Hepatitis C 1869 The modeled impact of improv 1842 The potential prevention imp 1794 Times they are a changing: H 1871 Treatment prioritization acc 1802 Trends in end-stage liver di 1868 Wisteria floribunda agglutin 1851 Ability of EMR-based fibrosi 1791 Access To Reimbursement Of I 1886 An Integrated Linkage to Car 1810 Benefits of Antiviral Treatm 1828 Can Hepatitis C be eliminate 1872 Cause of death in HCV patien 1789 Characteristics of Patients 1792 Comparative analysis of onli 1827 Comparison of On-Treatment H 1860 Development of End Stage Liv 1790 Distribution of pre-existing 1795 Does pregnancy protect again 1884 Evaluation of both Fucosylat 1809 Factors Associated with Hepa 1839 Fibrosis Progression in Pati 1841 From Care to a Cure: Improvi 1801 HCV in Semen of HIV-infected 1852 Hepatitis C Birth-Cohort Tes 1787 Hepatitis C Eradication with 1866 Hepatitis C RNA assay differ 1797 Hepatitis C Virus (HCV) Erad 1825 Hepatitis C Virus (HCV) Geno 1798 Hepatitis C Virus Genotype A 1820 Hepatitis C prevalence, dete 1846 Heterogeneous IL28B/IFNL4 di 1855 Hyperbilirubinemia in HIV-HC 1840 Impact of Hepatitis C (HCV) 1807 Impact of comorbidities on t 1863 Improvements in the Hepatiti 1870 Increasing Hepatitis C Virus 1811 Linkage to Care Outcomes for 1804 Liver fibrosis stage and com 1800 Natural History of Decompens 1815 Non-Invasive Fibrosis Scores 1843 Patients with Hepatitis C (H 1814 Perceived risk and HCV knowl 1864 Positive Impact of Point of 1831 Predictive value of APRI and 1887 Racial Differences in Socioe 1805 Rapid, sensitive, and accura 1858 Rectal Shedding of HCV in HC 89 Regression of Advanced Fibro 108 Serum levels of Wisteria flo 1838 The Association of Sustained 87 The Power of the Law: Improv 1875 The clinical profiles of Jap 1819 The epidemiology of hepatiti 1829 The use of hepatitis C core 1888 Treatment With Statins Reduc 1788 FO3. Therapeutics: Preclinical and Early Clinical Development A Single Dose of RG-101, a G 208 Miravirsen Dosing in Chronic 2255 Pharmacokinetics, Safety and 2260 Pharmacokinetics, Safety, an 2259 SB 9200 Shows Antiviral Acti 2262 Safety, Efficacy and Tolerab 2256 Short-term safety and pharma 2261 The effect of microRNA let-7 2264 Treatment with the Anti-miRN 2263 Discovery of AT-337 and AT-3 2266 Drug-Drug Interaction Studie 2265 EDP-239, a novel HCV NS5A in 2257 The impact of α-fetoprotein 2267 Toxicology evaluation of TT- 2258 FO4. Therapeutics: New Agents (not approved, phase 2-3) 98%–100% SVR4 in HCV Genot 41 A Randomized Controlled Tria 205 Absence of significant drug- 723 An Integrated Analysis of 40 42 An integrated safety analysi 716 Analysis of HCV Genotype 1 V 705 Baseline HCV NS5A resistance 709 Characterization of HCV Resi 718 Daclatasvir exposure alone d 728 Daclatasvir exposure does no 720 Daclatasvir in combination w 252 Daclatasvir plus sofosbuvir 206 Drug-drug interactions betwe 710 Efficacy and Safety of Co-Fo 708 Efficacy and Safety of Ombit 714
Page 2 and 3:
208A AASLD ABSTRACTS HEPATOLOGY, Oc
Page 4 and 5:
Page 6 and 7:
Page 8 and 9:
Page 10 and 11:
Page 12 and 13:
Page 14 and 15:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
Page 290 and 291:
Page 292 and 293:
Page 294 and 295:
Page 296 and 297:
Page 298 and 299:
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
Page 306 and 307:
Page 308 and 309:
Page 310 and 311:
Page 312 and 313:
Page 314 and 315:
Page 316 and 317:
Page 318 and 319:
Page 320 and 321:
Page 322 and 323:
Page 324 and 325:
Page 326 and 327:
Page 328 and 329:
Page 330 and 331:
Page 332 and 333:
Page 334 and 335:
Page 336 and 337:
Page 338 and 339:
Page 340 and 341:
Page 342 and 343:
Page 344 and 345:
Page 346 and 347:
Page 348 and 349:
Page 350 and 351:
Page 352 and 353:
Page 354 and 355:
Page 356 and 357:
Page 358 and 359:
Page 360 and 361:
Page 362 and 363:
Page 364 and 365:
Page 366 and 367:
Page 368 and 369:
Page 370 and 371:
Page 372 and 373:
Page 374 and 375:
Page 376 and 377:
Page 378 and 379:
Page 380 and 381:
Page 382 and 383:
Page 384 and 385:
Page 386 and 387:
Page 388 and 389:
Page 390 and 391:
Page 392 and 393:
Page 394 and 395:
Page 396 and 397:
Page 398 and 399:
Page 400 and 401:
Page 402 and 403:
Page 404 and 405:
Page 406 and 407:
Page 408 and 409:
Page 410 and 411:
Page 412 and 413:
Page 414 and 415:
Page 416 and 417:
Page 418 and 419:
Page 420 and 421:
Page 422 and 423:
Page 424 and 425:
Page 426 and 427:
Page 428 and 429:
Page 430 and 431:
Page 432 and 433:
Page 434 and 435:
Page 436 and 437:
Page 438 and 439:
Page 440 and 441:
Page 442 and 443:
Page 444 and 445:
Page 446 and 447:
Page 448 and 449:
Page 450 and 451:
Page 452 and 453:
Page 454 and 455:
Page 456 and 457:
Page 458 and 459:
Page 460 and 461:
Page 462 and 463:
Page 464 and 465:
Page 466 and 467:
Page 468 and 469:
Page 470 and 471:
Page 472 and 473:
Page 474 and 475:
Page 476 and 477:
Page 478 and 479:
Page 480 and 481:
Page 482 and 483:
Page 484 and 485:
Page 486 and 487:
Page 488 and 489:
Page 490 and 491:
Page 492 and 493:
Page 494 and 495:
Page 496 and 497:
Page 498 and 499:
Page 500 and 501:
Page 502 and 503:
Page 504 and 505:
Page 506 and 507:
Page 508 and 509:
Page 510 and 511:
Page 512 and 513:
Page 514 and 515:
Page 516 and 517:
Page 518 and 519:
Page 520 and 521:
Page 522 and 523:
Page 524 and 525:
Page 526 and 527:
Page 528 and 529:
Page 530 and 531:
Page 532 and 533:
Page 534 and 535:
Page 536 and 537:
Page 538 and 539:
Page 540 and 541:
Page 542 and 543:
Page 544 and 545:
Page 546 and 547:
Page 548 and 549:
Page 550 and 551:
Page 552 and 553:
Page 554 and 555:
Page 556 and 557:
Page 558 and 559:
Page 560 and 561:
Page 562 and 563:
Page 564 and 565:
Page 566 and 567:
Page 568 and 569:
Page 570 and 571:
Page 572 and 573:
Page 574 and 575:
Page 576 and 577:
Page 578 and 579:
Page 580 and 581:
Page 582 and 583:
Page 584 and 585:
Page 586 and 587:
Page 588 and 589:
Page 590 and 591:
Page 592 and 593:
Page 594 and 595:
Page 596 and 597:
Page 598 and 599:
Page 600 and 601:
Page 602 and 603:
Page 604 and 605:
Page 606 and 607:
Page 608 and 609:
Page 610 and 611:
Page 612 and 613:
Page 614 and 615:
Page 616 and 617:
Page 618 and 619:
Page 620 and 621:
Page 622 and 623:
Page 624 and 625:
Page 626 and 627:
Page 628 and 629:
Page 630 and 631:
Page 632 and 633:
Page 634 and 635:
Page 636 and 637:
Page 638 and 639:
Page 640 and 641:
Page 642 and 643:
Page 644 and 645:
Page 646 and 647:
Page 648 and 649:
Page 650 and 651:
Page 652 and 653:
Page 654 and 655:
Page 656 and 657:
Page 658 and 659:
Page 660 and 661:
Page 662 and 663:
Page 664 and 665:
Page 666 and 667:
Page 668 and 669:
Page 670 and 671:
Page 672 and 673:
Page 674 and 675:
Page 676 and 677:
Page 678 and 679:
Page 680 and 681:
Page 682 and 683:
Page 684 and 685:
Page 686 and 687:
Page 688 and 689:
Page 690 and 691:
Page 692 and 693:
Page 694 and 695:
Page 696 and 697:
Page 698 and 699:
Page 700 and 701:
Page 702 and 703:
Page 704 and 705:
Page 706 and 707:
Page 708 and 709:
Page 710 and 711:
Page 712 and 713:
Page 714 and 715:
Page 716 and 717:
Page 718 and 719:
Page 720 and 721:
Page 722 and 723:
Page 724 and 725:
Page 726 and 727:
Page 728 and 729:
Page 730 and 731:
Page 732 and 733:
Page 734 and 735:
Page 736 and 737:
Page 738 and 739:
Page 740 and 741:
Page 742 and 743:
Page 744 and 745:
Page 746 and 747:
Page 748 and 749:
Page 750 and 751:
Page 752 and 753:
Page 754 and 755:
Page 756 and 757:
Page 758 and 759:
Page 760 and 761:
Page 762 and 763:
Page 764 and 765:
Page 766 and 767:
Page 768 and 769:
Page 770 and 771:
Page 772 and 773:
Page 774 and 775:
Page 776 and 777:
Page 778 and 779:
Page 780 and 781:
Page 782 and 783:
Page 784 and 785:
Page 786 and 787:
Page 788 and 789:
Page 790 and 791:
Page 792 and 793:
Page 794 and 795:
1000A AASLD ABSTRACTS HEPATOLOGY, O
Page 796 and 797:
Page 798 and 799:
Page 800 and 801:
Page 802 and 803:
Page 804 and 805:
Page 806 and 807:
Page 808 and 809:
Page 810 and 811:
Page 812 and 813:
Page 814 and 815:
Page 816 and 817:
Page 818 and 819:
Page 820 and 821:
Page 822 and 823:
Page 824 and 825:
Page 826 and 827:
Page 828 and 829:
Page 830 and 831:
Page 832 and 833:
Page 834 and 835:
Page 836 and 837:
Page 838 and 839:
Page 840 and 841:
Page 842 and 843:
Page 844 and 845:
Page 846 and 847:
Page 848 and 849:
Page 850 and 851:
Page 852 and 853:
Page 854 and 855:
Page 856 and 857:
Page 858 and 859:
Page 860 and 861:
Page 862 and 863:
Page 864 and 865:
Page 866 and 867:
Page 868 and 869:
Page 870 and 871:
Page 872 and 873:
Page 874 and 875:
Page 876 and 877:
Page 878 and 879:
Page 880 and 881:
Page 882 and 883:
Page 884 and 885:
Page 886 and 887:
Page 888 and 889:
Page 890 and 891:
Page 892 and 893:
Page 894 and 895:
Page 896 and 897:
Page 898 and 899:
Page 900 and 901:
Page 902 and 903:
Page 904 and 905:
Page 906 and 907:
Page 908 and 909:
Page 910 and 911:
Page 912 and 913:
Page 914 and 915:
Page 916 and 917:
Page 918 and 919:
Page 920 and 921:
Page 922 and 923:
Page 924 and 925:
Page 926 and 927:
Page 928 and 929:
Page 930 and 931:
Page 932 and 933:
Page 934 and 935:
Page 936 and 937:
Page 938 and 939:
Page 940 and 941:
Page 942 and 943:
Page 944 and 945:
Page 946 and 947:
Page 948 and 949:
Page 950 and 951:
Page 952 and 953:
Page 954 and 955:
Page 956 and 957:
Page 958 and 959:
Page 960 and 961:
Page 962 and 963:
Page 964 and 965:
Page 966 and 967:
Page 968 and 969:
Page 970 and 971:
Page 972 and 973:
Page 974 and 975:
Page 976 and 977:
Page 978 and 979:
Page 980 and 981:
Page 982 and 983:
Page 984 and 985:
Page 986 and 987:
Page 988 and 989:
Page 990 and 991:
Page 992 and 993:
Page 994 and 995:
Page 996 and 997:
Page 998 and 999:
Page 1000 and 1001:
Page 1002 and 1003:
Page 1004 and 1005:
Page 1006 and 1007:
Page 1008 and 1009:
Page 1010 and 1011:
Page 1012 and 1013:
Page 1014 and 1015:
Page 1016 and 1017:
Page 1018 and 1019:
Page 1020 and 1021:
Page 1022 and 1023:
Page 1024 and 1025:
Page 1026 and 1027:
Page 1028 and 1029:
Page 1030 and 1031:
Page 1032 and 1033:
Page 1034 and 1035:
Page 1036 and 1037:
Page 1038 and 1039:
Page 1040 and 1041:
Page 1042 and 1043:
Page 1044 and 1045:
Page 1046 and 1047:
Page 1048 and 1049:
Page 1050 and 1051:
Page 1052 and 1053:
Page 1054 and 1055:
Page 1056 and 1057:
Page 1058 and 1059:
Page 1060 and 1061:
Page 1062 and 1063:
Page 1064 and 1065:
Page 1066 and 1067:
Page 1068 and 1069:
Page 1070 and 1071:
Page 1072 and 1073:
Page 1074 and 1075:
Page 1076 and 1077:
Page 1078 and 1079:
Page 1080 and 1081:
Page 1082 and 1083:
Page 1084 and 1085:
Page 1086 and 1087:
Page 1088 and 1089:
Page 1090 and 1091:
Page 1092 and 1093:
Page 1094 and 1095:
Page 1096 and 1097:
Page 1098 and 1099:
Page 1100 and 1101:
Page 1102 and 1103:
Page 1104 and 1105:
Page 1106 and 1107:
1312A AUTHOR INDEX HEPATOLOGY, Octo
Page 1108 and 1109:
Page 1110 and 1111:
Page 1112 and 1113: 1318A AUTHOR INDEX HEPATOLOGY, Octo
Page 1160 and 1161: 1366A CATEGORY INDEX HEPATOLOGY, Oc
Page 1172: 1378A CATEGORY INDEX HEPATOLOGY, Oc
show all

studies

Create successful ePaper yourself

Delete template?

Save as template?